At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Oct. 02, 2024 8:00 AM ETAbbVie Inc. (ABBV) Per FDA requirement for this indication, Allergan Aesthetics is providing a product training program for providers, which includes facial anatomy and ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...
Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study. A retrospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results